Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SynGEM RSV Vaccine in Healthy Adults
NCT02958540Phase 1Unknown
- Sponsor
- Mucosis B.V.
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SynGEM in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Mucosis B.V. Primary endpoint: Safety and tolerability. Status: unknown.
02
Drugs
SynGEM
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02958540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958540.